Post-earnings recap
Reported
Wed, Nov 2, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a loss that was slightly worse than expected, contributing to a 2.84% decline in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's near-term performance. Management's focus on pipeline advancement suggests they are prioritizing long-term growth despite current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.21 | N/A | -1.77% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced this quarter but emphasized their commitment to pipeline development. They did not provide any forward guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite the current financial results.